In this guide, Ill explain GLP-1 medications in clear, practical terms: how they work, why they are prescribed, what benefits and risks matter most, and how the different options compare
5 The annual incidence ranges from 8.8 to 23.1 per 100,000 person-years in North America, 0.624.3 per 100,000 person-years in Europe, and 7.317.4 per 100,000 person-years in Oceania, with a prevalence in adults in their 30 s and 40 s
They improve insulin sensitivity
The evidence base for GLP-1 agonists in binge eating disorder remains preliminary, with most data coming from case reports, small case series, and secondary analyses rather than large randomized controlled trials specifically designed for BED
What symptoms require urgent contact or emergency care